PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML

Oncogene

Volumn 30, Issue 15, 2011, Pages 1822-1830

  Kurahashi, S ^a   Hayakawa, F ^a   Miyata, Y ^a   Yasuda, T ^a   Minami, Y ^a   Tsuzuki, S ^b   Abe, A ^a   Naoe, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

apoptosis; arsenic trioxide; DNA binding; nuclear body; PAX5; PML

Indexed keywords

ARSENIC TRIOXIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR PAX5;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; FUSION GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; CELL LINE; GENES, DOMINANT; HUMANS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 79954621829     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.554     Document Type: Article

References (43)

1. Atsumi A, Tomita A, Kiyoi H, Naoe T. (2006). Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun 345: 1471-1480. (Pubitemid 43817898)
2. Busslinger M. (2004). Transcriptional control of early B cell development. Annu Rev Immunol 22: 55-79. (Pubitemid 38680418)
3. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. (1996). Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 93: 6129-6134. (Pubitemid 26190815)
4. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353. (Pubitemid 27229821)
5. Czerny T, Schaffner G, Busslinger M. (1993). DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev 7: 2048-2061. (Pubitemid 23312955)
6. Dellaire G, Bazett-Jones DP. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26: 963-977. (Pubitemid 39273070)
7. Dyck JA, Maul GG, Miller Jr WH, Chen JD, Kakizuka A, Evans RM. (1994). A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333-343. (Pubitemid 24046695)
8. Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene MC, Beldjord K, De Vos J et al. (2009). PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 hap-loinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 23: 1989-1998.
9. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. (2008). PAX5/ TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 68: 181-189. (Pubitemid 351380119)
10. Hayakawa F, Abe A, Kitabayashi I, Pandolfi PP, Naoe T. (2008). Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J Biol Chem 283: 24420-24425.
11. Hayakawa F, Privalsky ML. (2004). Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5: 389-401. (Pubitemid 38482074)
12. Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H. (2004). Functional regulation of GATA-2 by acetylation. J Leukoc Biol 75: 529-540. (Pubitemid 38316385)
13. Holmes ML, Carotta S, Corcoran LM, Nutt SL. (2006). Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment. Genes Dev 20: 933-938.
14. Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC et al. (1996). The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88: 4110-4117. (Pubitemid 26399155)
15. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T et al. (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221-234.
16. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al. (2010). PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18: 88-98.
17. Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M et al. (2008). Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci USA 105: 11921-11926.
18. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T et al. (2001). Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7: 1233-1243. (Pubitemid 32607357)
19. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N et al. (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. Embo J 13: 1073-1083. (Pubitemid 24074714)
20. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. (1992). The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 12: 2662-2672.
21. Maier H, Ostraat R, Parenti S, Fitzsimmons D, Abraham LJ, Garvie CW et al. (2003). Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-alpha gene transcription by Pax-5 (BSAP). Nucleic Acids Res 31: 5483-5489. (Pubitemid 37441918)
22. Mikkola I, Heavey B, Horcher M, Busslinger M. (2002). Reversion of B cell commitment upon loss of Pax5 expression. Science 297: 110-113. (Pubitemid 34743105)
23. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. (2002). Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903. (Pubitemid 34792653)
24. Morrison AM, Nutt SL, Thevenin C, Rolink A, Busslinger M. (1998). Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Semin Immunol 10: 133-142. (Pubitemid 28339783)
25. Muller S, Matunis MJ, Dejean A. (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. Embo J 17: 61-70. (Pubitemid 28041048)
26. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758-764. (Pubitemid 46582031)
27. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA et al. (2009). Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23: 134-143.
28. Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S. (2007). Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol 139: 269-274. (Pubitemid 47493075)
29. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. (1999). Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324. (Pubitemid 29536124)
30. Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M. (2001). Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 20: 65-82. (Pubitemid 32500866)
31. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. (1998). Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 17: 2319-2333. (Pubitemid 28171916)
32. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. (2003). A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 101: 2932-2939. (Pubitemid 36857977)
33. Schebesta M, Pfeffer PL, Busslinger M. (2002). Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17: 473-485. (Pubitemid 35223536)
34. Souabni A, Cobaleda C, Schebesta M, Busslinger M. (2002). Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 17: 781-793. (Pubitemid 35477797)
35. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al. (1998a). Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551. (Pubitemid 28217080)
36. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R. et al. (1998b). PML is essential for multiple apoptotic pathways. Nat Genet 20: 266-272. (Pubitemid 28507671)
37. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M et al. (1994). Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76: 345-356. (Pubitemid 24046696)
38. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S et al. (2001). The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259-2268. (Pubitemid 32222080)
39. Yang S, Kuo C, Bisi JE, Kim MK. (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/ Chk2. Nat Cell Biol 4: 865-870. (Pubitemid 35331361)
40. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243.
41. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. (2000a). Role of SUMO-1-modified PML in nuclear body formation. Blood 95: 2748-2752.
42. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. (2000b). Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 191: 631-640.
43. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY et al. (1997). Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983. (Pubitemid 27180484)